Lisdexamfetamine in the treatment of methamphetamine dependence скачать в хорошем качестве

Lisdexamfetamine in the treatment of methamphetamine dependence

presented by Dr Nadine Ezard We conducted a randomised double-blind placebo controlled trial of 250mg lisdexamfetamine daily vs placebo among 164 adults with methamphetamine dependence at 6 outpatient services around Australia. The study was impacted by COVID19 and 43% of the sample dropped out of treatment prematurely. The lisdexamfetamine group reported 9 fewer days use over the 12-week period and greater self-reported treatment effectiveness and treatment satisfaction but this wasn’t sustained into the last 4 weeks of treatment, the primary endpoint. Results are consistent with recent ASAM guidelines recommending consideration closely monitored specialist off-label stimulant prescription for the treatment of stimulant use disorder and more work is required to understand the potential role of prescription amphetamines in the treatment landscape. Dr Nadine Ezard is an Addiction Medicine Specialist (MBBS, BA, MPH, PhD, FAChAM) and a founding fellow of the Australian Chapter of Addiction Medicine. She is a professor and the inaugural Director of the National Centre for Clinical Research on Emerging Drugs (NCCRED) with the Faculty of Medicine at the University of New South Wales. Also, since 2012, she has been the Clinical Director of the Alcohol and Drug Service at St Vincent’s Hospital Sydney, which serves people with a variety of substance use disorders in inpatient, outpatient and community settings and strives to embed innovation in practice. Previously, she worked for the World Health Organization, the United Nations High Commissioner for Refugees, and the United Nations Office of Drugs and Crime. Nadine has more than 30 years of clinical and research experience in addiction medicine and public health practice in Australian and international contexts. She is a worldwide recognised researcher in substance use and its translation into consumer-focused harm-reduction public health interventions, models of care and policy for vulnerable populations. Her current research focusses on working with people who use stimulants and related drugs to develop new and effective interventions, and she has a particular interest in substance use disorders among refugees and other displaced populations.